Abstract:Background：Dexmedetomidine(DEX)is a selective and potent ɑ2adrenergic receptor (ɑ2-AR) agonist.Objective:Summarize the research progress in dexmedetomidine treating ischemia/reperfusionin juryContent：It has also been demonstrated to have protective effects in a variety of .animal models of ischemia/reperfusion (I/R) injury, including the intestine, myocardial, renal, lung, cerebral and liver.DEX modulates gene expression, channel activation, transmitter release, inflammatory processes and apoptotic and necrotic cell death.Trend：The broad spectrum of biological activities associated with DEX continues to expand, and its diverse effects suggest that it may offer a novel therapeutic approach for the treatment of human diseases with I/R involvement.